Details of the Drug

General Information of Drug (ID: DMOBLGK)

Drug Name
Tromethamine
Synonyms
Trometamol; 77-86-1; TROMETHAMINE; Tris; Tris(Hydroxymethyl)aminomethane; Tham; Trisamine; 2-Amino-2-(hydroxymethyl)-1,3-propanediol; Trizma; Tris buffer; Tris base; Tromethane; Trisaminol; Talatrol; Trispuffer; Trisamin; Pehanorm; Tutofusin tris; Tris-steril; Apiroserum Tham; Addex-tham; Tris-base; Tris, free base; Trimethylolaminomethane; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris Amino; Aminotrimethylolmethane; Aminotris(hydroxymethyl)methane; THAM-E; Tris (buffering agent); Tris(Hydroxymethyl)Aminomethane
Indication
Disease Entry ICD 11 Status REF
Acidosis 5C73 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 121.14
Topological Polar Surface Area (xlogp) -2.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C4H11NO3
IUPAC Name
2-amino-2-(hydroxymethyl)propane-1,3-diol
Canonical SMILES
C(C(CO)(CO)N)O
InChI
InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
InChIKey
LENZDBCJOHFCAS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
6503
ChEBI ID
CHEBI:9754
CAS Number
77-86-1
DrugBank ID
DB03754
TTD ID
D03ZFN
ACDINA ID
D01507

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
S-adenosylmethionine decarboxylase proenzyme (AMD1) TTBFROQ DCAM_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acidosis
ICD Disease Classification 5C73
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
S-adenosylmethionine decarboxylase proenzyme (AMD1) DTT AMD1 4.41E-05 0.37 0.61
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tromethamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Choline salicylate DM8P137 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tromethamine caused by Choline salicylate mediated altered urine pH. Postoperative inflammation [1A00-CA43] [9]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Potassium phosphate monobasic E00429 516951 Buffering agent
Edetate disodium E00186 8759 Complexing agent
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tromethamine 10mg tablet 10mg Tablet Oral
Tromethamine 30mg/ml powder 30mg/ml Powder Intravenous
Tromethamine 60mg/2ml powder 60mg/2ml Powder Intravenous
Tromethamine 15.75mg spray 15.75mg Spray Nasal
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7328).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601.
5 Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. Pharmacol Res. 1996 Jan;33(1):67-70.
6 S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77.
7 New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407.
8 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
9 Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6. [PMID: 837963]